NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tvardi Therapeutics, Inc. TVRD
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-3.26
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 14-year series below
Revenue
Net income
Per share
USD -3.26
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-54.2%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−18.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−32.3%
−18.5%
+8.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+64.7%
Change, 10 years—
The share count grew 65% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 32.1M
total assets, end of FY2025
Total assetsUSD 32.1M
EquityUSD 20.9M
CashUSD 20.7M
Current ratio2.86×
Equity funds 65% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
·
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.26
−11.42
−26.26
−19.12
−1.74
0.18
−2.49
−2.06
−1.86
−2.10
−1.00
−0.85
−0.74
·
Dividend / sh $
0.00
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−245.1
−44.3
−37.1
3.9
−66.4
−67.2
−84.5
−73.5
−31.5
·
·
·
Shares out B
0.01
0.00
0.00
0.05
0.05
0.05
0.05
0.04
0.03
0.03
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 38
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed